OBJECTIVE: to investigate the epidemiology of infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia (VAP). DESIGN: prospective clinical study. SETTING: a medical-surgical ICU in a university hospital. PATIENTS: we followed-up 568 mechanically ventilated patients and 83 episodes of VAP with etiologic diagnosis in 72 patients were retained for analysis. RESULTS: Ps. aeruginosa was isolated in 22 (26.5%) episodes in 18 patients. Of these episodes 7 were directly responsible for death. Using logistic regression analysis, the risk of VAP due to Ps. aeruginosa was increased in patients with chronic obstructive pulmonary disease (relative risk (RR) = 29.9, 95% confidence interval (CI) = 4.86-184.53), a mechanical ventilation period longer than 8 days (RR = 8.1, 95% CI = 1.01-65.40) and prior use of antibiotics (RR = 5.5, 95% CI = 0.88-35.01). CONCLUSIONS: patients with VAP and these factors have a greater risk of infection by Ps. aeruginosa and empirical therapy for these episodes should include anti-pseudomonal activity until etiologic diagnosis is established.
OBJECTIVE: to investigate the epidemiology of infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia (VAP). DESIGN: prospective clinical study. SETTING: a medical-surgical ICU in a university hospital. PATIENTS: we followed-up 568 mechanically ventilated patients and 83 episodes of VAP with etiologic diagnosis in 72 patients were retained for analysis. RESULTS:Ps. aeruginosa was isolated in 22 (26.5%) episodes in 18 patients. Of these episodes 7 were directly responsible for death. Using logistic regression analysis, the risk of VAP due to Ps. aeruginosa was increased in patients with chronic obstructive pulmonary disease (relative risk (RR) = 29.9, 95% confidence interval (CI) = 4.86-184.53), a mechanical ventilation period longer than 8 days (RR = 8.1, 95% CI = 1.01-65.40) and prior use of antibiotics (RR = 5.5, 95% CI = 0.88-35.01). CONCLUSIONS:patients with VAP and these factors have a greater risk of infection by Ps. aeruginosa and empirical therapy for these episodes should include anti-pseudomonal activity until etiologic diagnosis is established.
Authors: T G Emori; D H Culver; T C Horan; W R Jarvis; J W White; D R Olson; S Banerjee; J R Edwards; W J Martone; R P Gaynes Journal: Am J Infect Control Date: 1991-02 Impact factor: 2.918
Authors: Hervé Dupont; Philippe Montravers; Rémy Gauzit; Benoît Veber; Jean-Louis Pouriat; Claude Martin Journal: Intensive Care Med Date: 2003-01-14 Impact factor: 17.440
Authors: Ignacio Martin-Loeches; Maria Deja; Despoina Koulenti; George Dimopoulos; Brian Marsh; Antonio Torres; Michael S Niederman; Jordi Rello Journal: Intensive Care Med Date: 2013-01-29 Impact factor: 17.440
Authors: D Koulenti; S Blot; J M Dulhunty; L Papazian; I Martin-Loeches; G Dimopoulos; C Brun-Buisson; M Nauwynck; C Putensen; J Sole-Violan; A Armaganidis; J Rello Journal: Eur J Clin Microbiol Infect Dis Date: 2015-09-25 Impact factor: 3.267